SENP2 regulates hepatocellular carcinoma cell growth by modulating the stability of β-catenin

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 8, 2012, Pages 3583-3587

  Shen, Huo Jian ^a   Zhu, Hong Yi ^a   Yang, Chao ^a   Ji, Fu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

hepatocellular carcinoma; Hepg2 cells; Senp2; Catenin

Indexed keywords

EID: 84873652268     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.8.3583     Document Type: Article

References (22)

1. Anson M, Crain-Denoyelle AM, Baud V, et al. (2012). Oncogenic beta-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest, 122, 586-99.
2. Bawa-Khalfe T, Yeh ET (2010). SUMO Losing Balance: SUMO Proteases Disrupt SUMO Homeostasis to Facilitate Cancer Development and Progression. Genes Cancer, 1, 748-52.
3. Cavard, C, S Colnot, V Audard, et al. (2008). Wnt/beta-catenin pathway in hepatocellular carcinoma pathogenesis and liver physiology. Future Oncol, 4, 647-60.
4. Cheng J, Bawa T, Lee P, et al. (2006). Role of desumoylation in the development of prostate cancer. Neoplasia, 8, 667-76.
5. Cheng J, Kang X, Zhang S, et al. (2007). SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia.Cell, 131, 584-95.
6. Chiu SY, Asai N, Costantini F, et al. (2008). SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages. PLoS Biol, 6, e310.
7. David R (2010). Sumoylation: Targeting SUMO. Nat Rev Mol Cell Biol, 11, 387.
8. Di Bacco A, Gill G (2006). SUMO-specific proteases and the cell cycle. An essential role for SENP5 in cell proliferation. Cell Cycle, 5, 2310-3.
9. Geiss-Friedlander R, Melchior F (2007). Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol, 8, 947-56.
10. Haindl M, Harasim T, Eick T, et al. (2008). The nucleolar SUMO-specific protease SENP3 reverses SUMO modification of nucleophosmin and is required for rRNA processing. EMBO Rep, 9, 273-9.
11. Hang J, Dasso M (2002). Association of the human SUMO-1 protease SENP2 with the nuclear pore. J Biol Chem, 277, 19961-6.
12. Huang H, He X (2008). Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol, 20, 119-25.
13. Itahana Y, Yeh ET, Zhang Y (2006). Nucleocytoplasmic shuttling modulates activity and ubiquitination-dependent turnover of SUMO-specific protease 2. Mol Cell Biol, 26, 4675-89.
14. Kang X, Qi Y, Zuo Y, et al. (2010). SUMO-specific protease 2 is essential for suppression of polycomb group protein-mediated gene silencing during embryonic development. Mol Cell, 38, 191-201.
15. Lam AP, Gottardi CJ (2011). Beta-catenin signaling: a novel mediator of fibrosis and potential therapeutic target. Curr Opin Rheumatol, 23, 562-7.
16. Li SJ, Hochstrasser M (1999). A new protease required for cell-cycle progression in yeast. Nature, 398, 246-51.
17. MacDonald BT, Tamai K, He X (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell, 17, 9-26.
18. Vertegaal AC (2010). SUMO chains: polymeric signals. Biochem Soc Trans, 38, 46-49.
19. Wang Y, Dasso M (2009). SUMOylation and deSUMOylation at a glance. J Cell Sci, 122, 4249-52.
20. White BD, Chien AJ, Dawson DW (2012). Dysregulation of Wnt/beta-catenin signaling in gastrointestinal cancers. Gastroenterology, 142, 219-32.
21. Woo CH, Abe J (2010). SUMO-a post-translational modification with therapeutic potential? Curr Opin Pharmacol, 10, 146-55.
22. Zhang XF, Tan X, Zeng G, et al. (2010). Conditional beta-catenin loss in mice promotes chemical hepatocarcinogenesis: role of oxidative stress and platelet-derived growth factor receptor alpha/phosphoinositide 3-kinase signaling. Hepatology, 52, 954-65.